The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cyclin-dependent kinases (CDKs) are crucial for cell-cycle regulation and represent significant therapeutic targets in cancer treatment.
• CDK4/6 inhibitors have demonstrated success in breast cancer, validating CDK inhibition's clinical potential.
• Despite successes, CDK4/6 inhibitors are currently approved only for breast cancer, highlighting the need for broader applications.

Purpose of the Study:

• To review the evolution of CDK inhibitor clinical use over the past decade.
• To explore emerging strategies for expanding CDK inhibitor applications to other cancer types.
• To discuss advancements in overcoming resistance and mitigating toxicity for CDK inhibitors.

Main Methods:

• Review of recent clinical studies and research findings on CDK inhibitors.
• Analysis of combinatorial approaches with targeted therapies (e.g., HER2, PI3K inhibitors).
• Examination of insights into resistance mechanisms and development of next-generation inhibitors.
• Assessment of biomarker development for patient selection.

Main Results:

• CDK4/6 inhibitors have transformed breast cancer treatment, with ongoing research exploring new indications.
• Combinatorial therapies and understanding resistance mechanisms are expanding the therapeutic scope of CDK inhibitors.
• Development of selective CDK2 inhibitors and next-generation CDK4 inhibitors aims to treat refractory disease and reduce toxicity.
• Biomarkers are emerging as tools for patient selection, though clinical utility is still developing.

Conclusions:

• The clinical application of CDK inhibitors has significantly evolved since their initial approval.
• New therapeutic strategies, including combinations and next-generation inhibitors, hold promise for broader cancer treatment.
• Further research into biomarkers and resistance mechanisms is crucial for maximizing the potential of CDK inhibitors in oncology.